Both EGFR inhibitors, erlotinib and BIBW2992, were tested preclinically using the CCSP-rtTA; Tet-O7-EGFRL858R model [26, 37, 49, 68, 70]. In vivo, both therapies resulted in dramatic tumour regression, however, phase I clinical trials for BIBW2992 resulted in no significant partial or complete responses in patients [70]. The gene discussed is EGFR; the disease is neoplasm.